CNBC: Gilead says early results of coronavirus drug trial show improvement with shorter remdesivir treatment
Gilead Sciences said Wednesday preliminary results of a coronavirus drug trial showed at least 50% of patients treated with a 5-day dosage of antiviral drug remdesivir improved.
This is still in the early stages and hasn’t been tested vs. a placebo yet.
BREAKING: Gilead says it is aware of positive data emerging from its remdesivir drug study to treat #COVID19, pushing futures higher. @megtirrell and @ScottGottliebMD weigh in with their thoughts: pic.twitter.com/bqcxm9D8PN
— Squawk Box (@SquawkCNBC) April 29, 2020
